Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleBasic Science Investigation
Open Access

Tandem Isotope Therapy with 225Ac- and 177Lu-PSMA-617 in a Murine Model of Prostate Cancer

Catherine Meyer, Andreea Stuparu, Katharina Lueckerath, Jeremie Calais, Johannes Czernin, Roger Slavik and Magnus Dahlbom
Journal of Nuclear Medicine November 2023, 64 (11) 1772-1778; DOI: https://doi.org/10.2967/jnumed.123.265433
Catherine Meyer
1Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andreea Stuparu
1Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Katharina Lueckerath
1Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California; and
2Clinic for Nuclear Medicine, University Hospital Essen, Essen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeremie Calais
1Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Johannes Czernin
1Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Roger Slavik
1Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Magnus Dahlbom
1Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 64 no. 11 1772-1778
DOI 
https://doi.org/10.2967/jnumed.123.265433
PubMed 
37797974

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Received for publication January 13, 2023
  • Revision received June 17, 2023
  • Published online November 2, 2023.

Article Versions

  • previous version (October 5, 2023 - 06:30).
  • You are viewing the most recent version of this article.
Copyright & Usage 
© 2023 by the Society of Nuclear Medicine and Molecular Imaging. Immediate Open Access: Creative Commons Attribution 4.0 International License (CC BY) allows users to share and adapt with attribution, excluding materials credited to previous publications. License: https://creativecommons.org/licenses/by/4.0/. Details: http://jnm.snmjournals.org/site/misc/permission.xhtml.

Author Information

  1. Catherine Meyer1,
  2. Andreea Stuparu1,
  3. Katharina Lueckerath1,2,
  4. Jeremie Calais1,
  5. Johannes Czernin1,
  6. Roger Slavik1 and
  7. Magnus Dahlbom1
  1. 1Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California; and
  2. 2Clinic for Nuclear Medicine, University Hospital Essen, Essen, Germany
  1. For correspondence or reprints, contact Magnus Dahlbom (mdahlbom{at}mednet.ucla.edu).
View Full Text

Statistics from Altmetric.com

Cited By...

  • 12 Citations
  • 12 Citations
  • Google Scholar

This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.

  • Future Treatment Strategies for Cancer Patients Combining Targeted Alpha Therapy with Pillars of Cancer Treatment: External Beam Radiation Therapy, Checkpoint Inhibition Immunotherapy, Cytostatic Chemotherapy, and Brachytherapy
    Ruth Christine Winter, Mariam Amghar, Anja S. Wacker, Gábor Bakos, Harun Taş, Mareike Roscher, James M. Kelly, Martina Benešová-Schäfer
    Pharmaceuticals 2024 17 8
  • 225Ac-PSMA-617 Augmentation in High-Risk mCRPC Undergoing 177Lu-PSMA-617 Radioligand Therapy
    Florian Rosar, Caroline Burgard, Luna Vanessa Rohloff, Arne Blickle, Mark Bartholomä, Stephan Maus, Sven Petto, Andrea Schaefer-Schuler, Samer Ezziddin
    Clinical Nuclear Medicine 2024 49 7
  • Harnessing the power of f-block elements in radiopharmaceuticals
    Alex Rigby, Trevor Arino
    Nature Reviews Chemistry 2024 8 5
  • Single Chelator–Minibody Theranostic Agents for89Zr PET Imaging and177Lu Radiopharmaceutical Therapy of PSMA-Expressing Prostate Cancer
    Khanh-Van Ho, David S. Tatum, Lisa Watkinson, Terry Carmack, Fang Jia, Alessandro Mascioni, Charles A. Maitz, Darren Magda, Carolyn J. Anderson
    Journal of Nuclear Medicine 2024 65 9
  • Analysis of Molecular Imaging Biomarkers Derived from [18F]FDG PET/CT in mCRPC: Whole-Body Total Lesion Glycolysis (TLG) Predicts Overall Survival in Patients Undergoing [225Ac]Ac-PSMA-617-Augmented [177Lu]Lu-PSMA-617 Radioligand Therapy
    Caroline Burgard, Fadi Khreish, Lukas Dahlmanns, Arne Blickle, Moritz B. Bastian, Tilman Speicher, Stephan Maus, Andrea Schaefer-Schuler, Mark Bartholomä, Sven Petto, Samer Ezziddin, Florian Rosar
    Cancers 2024 16 20
  • Computationally efficient collimator-detector response compensation in high energy SPECT using 1D convolutions and rotations
    Lucas A Polson, Pedro Esquinas, Sara Kurkowska, Chenguang Li, Peyman Sheikhzadeh, Mehrshad Abbassi, Saeed Farzanehfar, Seyyede Mirabedian, Carlos Uribe, Arman Rahmim
    Physics in Medicine & Biology 2025 70 2
  • DNA Damage and Repair in PBMCs after Internal Ex Vivo Irradiation with [223Ra]RaCl2 and [177Lu]LuCl3 Mixtures
    Isabella Strobel, Sarah Schumann, Jessica Müller, Andreas K. Buck, Matthias Port, Michael Lassmann, Uta Eberlein, Harry Scherthan
    International Journal of Molecular Sciences 2024 25 16
  • Hematological toxicity of [225Ac]Ac-PSMA-617 and [177Lu]Lu-PSMA-617 in RM1-PGLS syngeneic mouse model
    Meryl Maria Vilangattil, Abir Swaidan, Jonathan Godinez, Marco F. Taddio, Johannes Czernin, Christine E. Mona, Giuseppe Carlucci
    EJNMMI Radiopharmacy and Chemistry 2025 10 1
  • Highlight selection of radiochemistry and radiopharmacy developments by editorial board
    Jun Toyohara, Danielle Vugts, Oliver C. Kiss, Sergio Todde, Xiang-Guo Li, Zhibo Liu, Zhi Yang, Nic Gillings, Emiliano Cazzola, Wiktor Szymanski, Nick van der Meulen, Raymond Reilly, Carlotta Taddei, Ralf Schirrmacher, Zijing Li, Yohannes Jorge Lagebo, Naoual Bentaleb, Marta de Souza Albernaz, Suzanne Lapi, Caterina Ramogida, Archana Mukherjee, Javier Ajenjo, Winnie Deuther-Conrad, Cécile Bourdeau
    EJNMMI Radiopharmacy and Chemistry 2024 9 1
  • Impact of cell geometry, cellular uptake region, and tumour morphology on 225Ac and 177Lu dose distributions in prostate cancer
    Cassandra Miller, Ivan Klyuzhin, Guillaume Chaussé, Julia Brosch-Lenz, Helena Koniar, Kuangyu Shi, Arman Rahmim, Carlos Uribe
    EJNMMI Physics 2024 11 1

Article usage

Article usage: October 2023 to April 2025

AbstractFullPdf
Oct 2023908615357
Nov 2023594664212
Dec 202313123593
Jan 202410833095
Feb 20245833969
Mar 202468263136
Apr 202462306100
May 20244221372
Jun 20242623760
Jul 20242243185
Aug 20242233071
Sep 20242922386
Oct 20244026689
Nov 20244326883
Dec 20242116557
Jan 20252317757
Feb 20253628192
Mar 20252522968
Apr 202525310109
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 64 (11)
Journal of Nuclear Medicine
Vol. 64, Issue 11
November 1, 2023
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Tandem Isotope Therapy with 225Ac- and 177Lu-PSMA-617 in a Murine Model of Prostate Cancer
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Tandem Isotope Therapy with 225Ac- and 177Lu-PSMA-617 in a Murine Model of Prostate Cancer
Catherine Meyer, Andreea Stuparu, Katharina Lueckerath, Jeremie Calais, Johannes Czernin, Roger Slavik, Magnus Dahlbom
Journal of Nuclear Medicine Nov 2023, 64 (11) 1772-1778; DOI: 10.2967/jnumed.123.265433

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Tandem Isotope Therapy with 225Ac- and 177Lu-PSMA-617 in a Murine Model of Prostate Cancer
Catherine Meyer, Andreea Stuparu, Katharina Lueckerath, Jeremie Calais, Johannes Czernin, Roger Slavik, Magnus Dahlbom
Journal of Nuclear Medicine Nov 2023, 64 (11) 1772-1778; DOI: 10.2967/jnumed.123.265433
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Visual Abstract
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF

Related Articles

  • PubMed
  • Google Scholar

Cited By...

  • Single Chelator-Minibody Theranostic Agents for 89Zr PET Imaging and 177Lu Radiopharmaceutical Therapy of PSMA-Expressing Prostate Cancer
  • Google Scholar

More in this TOC Section

  • Establishing In Vitro Dosimetric Models and Dose–Effect Relationships for 177Lu-DOTATATE in Neuroendocrine Tumors
  • Designed Ankyrin Repeat Protein–Mediated Peptide Nucleic Acid–Based Pretargeting: A Proof-of-Principle Study
  • [11C]ZTP-1: An Effective Short-Lived Radioligand for PET of Rat and Monkey Brain Phosphodiesterase Type 4 Subtype B
Show more Basic Science Investigation

Similar Articles

Keywords

  • PSMA-617
  • 177Lu
  • 225Ac
  • mouse model
  • prostate cancer
  • RLT
SNMMI

© 2025 SNMMI

Powered by HighWire